



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 11th August 2023

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Sub: Outcome of Board Meeting under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Ref: Submission of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2023 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., **Friday, 11th August, 2023** at its Registered Office, the Board inter alia has transacted the following business:

1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and three months ended 30th June, 2023, along with Limited Review Report thereon.

A Copy of Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and three months ended 30th June, 2023, along with Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015, is enclosed herewith.

2. The 41st Annual General Meeting of the Company shall be convened on September 29, 2023 through Video Conferencing (VC) / Other Audio-Visual Means (OVAM).

The aforesaid information and Financial Results are being made available on the Company's website at www.naxparlab.com



- TEL. : 022 - 6825 2525
- FAX : 022 - 2405 7708
- E-Mail : info@naxparlab.com
- Visit us at: www.naxparlab.com
- CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

The meeting of the Board of Directors Commenced at 5.00 P.M. and Concluded at 05.30 P.M.

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For Parnax Lab Limited



Preet Kukreja
Company Secretary & Compliance Officer
ACS No.: 56761

Encl: As above



C. N. PATEL & CO.
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,
Opp. Tidke Vidyalaya, Katol Road, Nagpur - 440013.
Tel. No. +91 712 2584800, 9922584800
Email ID : info@cnpca.in : www.cnpca.in

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** (“the company”) for the quarter ended June 30, 2023 together with the relevant notes thereon (“the Statement”). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C. N. Patel & Co.
Chartered Accountants
Firm’s Registration No. : 112552W

CA Manish Mandhana
Partner
M. No. : 112026

Place : Mumbai
Dated : 11th August, 2023

UDIN : 23112026BGVHCB3190



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
I	Revenue from Operations	113.23	244.26	311.31	747.38
II	Other Income	11.48	13.87	7.84	37.08
III	Total Revenue (I+II)	124.71	258.13	319.15	784.46
IV	Expenses				
	a) Cost of Material Consumed	41.41	54.88	52.59	164.63
	b) Purchase of Stock in trade	27.30	19.60	118.28	182.84
	c) Changes in inventories of finished goods, Work in progress and stock in trade		-		-
	d) Employee benefits expenses	14.21	10.68	13.71	55.21
	e) Finance Costs	3.58	3.21	10.57	24.90
	f) Depreciation and amortisation expenses	1.08	3.41	1.11	6.78
	g) Other expenses	28.19	67.13	67.60	187.41
	Total Expenses (IV)	115.77	158.91	263.87	621.77
V	Profit/(loss) before exceptional items and tax (III-IV)	8.94	99.22	55.28	162.69
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	8.94	99.22	55.28	162.69
VIII	Tax expense	2.29	26.54	14.26	42.23
IX	Profit/ (Loss) for the period (VII-VIII)	6.65	72.68	41.02	120.46
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	(6.78)	-	(6.78)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	1.71	-	1.72
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	(5.07)	-	(5.08)
XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	6.65	67.61	41.02	115.38
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.56	1,148.56	981.49	1,148.56
XIV	Earning per equity share (Not Annualised)				
	(1) Basic	0.06	0.66	0.42	1.09
	(2) Diluted	0.06	0.66	0.42	1.09

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2023.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2023
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board
For Parnax Lab Limited



(Signature)

Place : Mumbai
Date : 11-08-2023

Prakash M Shah
Director & CEO
DIN NO: 00440980



C. N. PATEL & CO.
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,
Opp. Tidke Vidyalaya, Katol Road, Nagpur - 440013.
Tel. No. +91 712 2584800, 9922584800
Email ID : info@cnpca.in : www.cnpca.in

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** (“the Parent”) and **Naxpar Pharma Private Limited** (“the Subsidiary”) (the Parent and its subsidiary together referred to as “the Group”) for the quarter ended June 30, 2023 together with the relevant notes thereon (“the Statement”). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the Parent’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities

Parnax Lab Limited	Holding Company
Naxpar Pharma Private Limited	Subsidiary


5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information in respect of one subsidiary, whose unaudited interim financial results include total revenues of Rs. 4,786.67 lakhs for the quarter ended June 30, 2023, total net profit of Rs. 326.23 lakhs for the quarter ended June 30, 2023, total comprehensive income of Rs. Nil for the quarter ended June 30, 2023, as considered in the Statement which has been reviewed by its independent auditor. The independent auditor review reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated above in paragraph 6 above, is not modified with respect to our reliance on the work done and the reports of the other auditors.

For C. N. Patel & Co.
Chartered Accountants
Firm's Registration No. : 112552W


CA Manish Mandhana
Partner
M. No. : 112026



Place : Mumbai
Dated : 11th August, 2023

UDIN : 23112026BGVHCC4761

PARNAX LAB LIMITED
 GALA NO. 114, BLDG NO 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
 Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com
 CIN:-L36912MH1982PLC027925
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023

S. No.	Particulars	Quarter Ended			(Rs. in Lakhs)
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
I	Revenue from Operations	4,874.18	4,090.68	3,673.93	16,760.69
II	Other Income	24.44	26.98	12.25	77.22
III	Total Revenue (I+II)	4,898.62	4,117.66	3,686.18	16,837.91
IV	Expenses				
	a) Cost of Material Consumed	2,692.88	2,177.55	1,779.40	8,840.91
	b) Purchase of Stock in trade	27.86	12.96	58.48	93.88
	c) Changes in inventories of finished goods, Work in progress and stock in trade	32.84	(19.07)	(23.43)	(53.37)
	d) Employee benefits expenses	568.13	530.32	466.52	2,005.31
	e) Finance Cost	115.71	118.49	126.23	495.10
	f) Depreciation and amortisation expenses	160.18	158.85	165.62	652.91
	g) Other expenses	902.95	915.26	861.82	3,575.22
	Total Expenses (IV)	4,500.55	3,894.36	3,434.63	15,609.94
V	Profit/(loss) before exceptional items and tax (III-IV)	398.07	223.30	251.55	1,227.97
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	398.07	223.30	251.55	1,227.97
VIII	Tax expense	65.19	79.30	58.31	364.67
IX	Profit/ (Loss) After Tax for the period (VII-VIII)	332.88	144.00	193.24	863.30
X	Minority Interest Profit (Loss)	0.65	0.15	0.30	1.49
XI	Profit/ (Loss) after share of Profit (Loss) of Minority Interest	332.23	143.85	192.94	861.81
XII	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	(13.80)	-	(13.80)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	3.66	-	3.66
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XIII	Total Other Comprehensive Income for the period	-	(10.14)	-	(10.14)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX + XIII)	332.88	133.86	193.24	853.16
XV	Total profit/(loss) for the year attributable to:				
	- Owners of the Company	332.23	143.85	192.94	861.81
	- Non-controlling interests	0.65	0.15	0.30	1.49
XVI	Other Comprehensive income attributable to:				
	- Owners of the Company	-	(10.13)	-	(10.13)
	- Non-controlling interests	-	(0.01)	-	(0.01)
XVII	Total Comprehensive income attributable to:				
	- Owners of the Company	332.23	133.72	192.94	851.68
	- Non-controlling interests	0.65	0.14	0.30	1.48
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	1,148.96	1,148.96	981.49	1,148.96
XIX	Earning per equity share (Not Annualised)				
	(1) Basic	2.90	1.30	1.97	7.80
	(2) Diluted	2.90	1.30	1.97	7.80

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2023
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2023
- EPS for quarter ended is on non annualised basis
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board
For Parnax Lab Limited



(Signature)

Place : Mumbai
Date : 11-08-2023

Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980